GPH 102
Alternative Names: GPH-102Latest Information Update: 26 Mar 2024
Price :
$50 *
At a glance
- Originator Graphite Bio
- Developer LENZ Therapeutics
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Beta-thalassaemia
Most Recent Events
- 21 Mar 2024 LENZ Therapeutics has merged with Graphite Bio to form LENZ Therapeutics
- 06 Jan 2023 Graphite Bio no longer expects to submit IND in mid-2024
- 09 Jun 2022 Pharmacodynamics data from a preclinical trial in Beta-thalassaemia presented at the 27th Congress of the European Haematology Association (EHA-2022)